

UPDATED EXHIBIT LIST – IPR2017-01103

| EX | Description |
|-------------|---|
| 2001 | Declaration of Nicholas A. Peppas, Sc.D. In Support of Patent Owner’s Preliminary Response |
| 2002 | Frye, D. K., Taxane Chemotherapy–Advances in Treatment for Breast Cancer. US Oncological Disease. 2006; 1(1):40–41 |
| 2003 | Paclitaxel (Taxol®) Formulation and Prodrugs: The Chemistry and Pharmacology of Taxol® and its Derivatives, Elsevier B.V. 1995; 103–130 |
| 2004 | Gelderblom <i>et al.</i> , Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37:1590–1598 |
| 2005 | Desai <i>et al.</i> , US 5,916,596, “Protein Stabilized Pharmacologically Active Agents, Methods for the Preparation Thereof and Methods for the Use Thereof” (issued Jun. 29,1999) |
| 2006 | FDA News. “Phase III Trial of Tocosol Paclitaxel Does Not Meet Primary Endpoint” (published 2017) |
| 2007 | Paz-Ares <i>et al.</i> , Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Brit J Cancer. 2008; 98:1608–1613 |
| 2008 | Langer <i>et al.</i> , Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer. J Thorac Oncol. 2008; 3:623–630 |
| 2009 | Hamaguchi <i>et al.</i> , NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel, Brit J Cancer. 2005; 92:1240–1246 |
| 2010 | FirstWord Pharma, “Results of Phase III study of NK105, a novel macromolecular micelle encapsulating an anticancer drug” (created July 12, 2016) |
| 2011 | Full Prescribing Information, Abraxane® , revised July 2015 |
| 2012 | Schnitzer <i>et al.</i> , Albondin-mediated Capillary Permeability to Albumin. J Biol Chem. 1994; 269(8):6072–6082 |
| 2013 | Schnitzer J.E., gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am J Physiol. |

Filed on behalf of: Abraxis Bioscience, LLC

Filed: November 7, 2017

| | |
|-------------|---|
| | 1992; 262:H246–H254 |
| 2014 | John <i>et al.</i> , Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. <i>Am J Physiol-Lung C.</i> 2003; 284:L187–L196 |
| 2015 | Laino, C., June 3, 2009, “Abraxane Beats Standard Breast Cancer Treatment” www.webmd.com/breast-cancer/news/20090609/breast-cancer-drug-abraxane-is-effective |
| 2016 | Blum <i>et al.</i> , Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes. <i>Clin Breast Cancer.</i> 2007; 7(11):850–856 |
| 2017 | Gradishar <i>et al.</i> , Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared with Polyethylated Castor Oil-Based Paclitaxel in Women with Breast Cancer. <i>J Clin Oncol.</i> 2005; 23(31):7794–7803 |
| 2018 | Zhang <i>et al.</i> , Nab-Paclitaxel is an Active Drug in Preclinical Model of Pediatric Solid Tumors. <i>Clin Cancer Res.</i> 2013; 19(21):5972–5983 |
| 2019 | Irizarry <i>et al.</i> , Cremophor EL-containing paclitaxel-induced anaphylaxis: a call to action. <i>Community Oncology.</i> 2009; 6(3):132–134 |
| 2020 | Rajeshkumar <i>et al.</i> , Superior Therapeutic Efficacy of nab-Paclitaxel over Cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. <i>Brit J Cancer.</i> 2016; 115:442–453 |
| 2021 | Wani, <i>et al.</i> , Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from <i>Taxus brevifolia</i> . <i>J Am Chem Soc.</i> 1971; 93(9):2325–7 |
| 2022 | <i>Intentionally Left Blank</i> |
| 2023 | Chromatographic Techniques for the Characterization of Proteins: Physical Methods to Characterize Pharmaceutical Proteins, Springer Science and Business Media, New York, NY, 1995, Vol. 7:243–299 |
| 2024 | Girard <i>et al.</i> , Separation of Human Serum Albumin Components by RP-HPLC and CZE and their Characterization by ESI-MS. <i>Chromatographia.</i> 1999; 49: S21–S27 |
| 2025 | The Application of HPLC for Proteins, High Performance Liquid Chromatography: Principles and Methods in Biotechnology. John Wiley & Sons, Chichester, UK, 1996, 411–467 |
| 2026 | Sparreboom <i>et al.</i> , Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high- |

Filed on behalf of: Abraxis Bioscience, LLC

Filed: November 7, 2017

| | |
|------|---|
| | performance liquid chromatography with ultraviolet detection. J. Chromatogr B. 1998; 705:159–164 |
| 2027 | Martin <i>et al.</i> , Assay of paclitaxel (Taxol) in plasma and urine by high-performance liquid chromatography. J. Chromatogr B. 1998; 709:281–288 |
| 2028 | Tian <i>et al.</i> , Degradation of Paclitaxel and Related Compounds in Aqueous Solutions I: Epimerization. J Pharm Sci. 2008; 97(3):1224–1235 |
| 2029 | Tian <i>et al.</i> , Degradation of Paclitaxel and Related Compounds in Aqueous Solutions II: Nonepimerization Degradation Under Neutral to Basic pH Conditions. J Pharm Sci. 2008; 97(8):3100–3108 |
| 2030 | Tian <i>et al.</i> , Degradation of Paclitaxel and Related Compounds in Aqueous Solutions III: Degradation Under Acidic pH Conditions and Overall Kinetics. J Pharm Sci. 2010; 99(3):1288–1298 |
| 2031 | Pillai <i>et al.</i> , Pharmaceutical Glass Interactions: A Review of Possibilities. J Pharm Sci & Res. 2016; Vol. 8(2):103–111 |
| 2032 | “Sticky Containers, Vanishing Drugs” http://blogs.sciencemag.org/pipeline/archives/2008/08/29/sticky_containers_vanishing_drugs (August 29, 2008) |
| 2033 | Mani <i>et al.</i> , Delivery of paclitaxel from cobalt–chromium alloy surfaces without polymeric carriers. Biomaterials. 2010; 31(20):5372–5384 |
| 2034 | Green <i>et al.</i> , Measurement of paclitaxel and its metabolites in human plasma using liquid chromatography/ion trap mass spectrometry with a sonic spray ionization interface. Rapid Commun Mass Sp. 2006; 20(14):2183–2189 |
| 2035 | Heldman <i>et al.</i> , Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis. Circulation. 2001; 103:2289–2295 |
| 2036 | Fukazawa <i>et al.</i> , Reduction of non-specific adsorption of drugs to plastic containers used in bioassays or analyses. J Pharmacol Tox Met. 2010; 61:329–333 |
| 2037 | Hunz <i>et al.</i> , Plasma And Tissue Pharmacokinetics Of Epirubicin And Paclitaxel In Patients Receiving Neoadjuvant Chemotherapy For Locally Advanced Primary Breast Cancer. Clin Pharmacol Ther. 2007; 81(5):659–668 |
| 2038 | Pfeifer <i>et al.</i> , Precipitation of paclitaxel during infusion by pump. Am J Hosp Pharm. 1993; 50:2518–2521 |

Filed on behalf of: Abraxis Bioscience, LLC

Filed: November 7, 2017

| | |
|-------------|--|
| 2039 | Xu <i>et al.</i> , Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 °C. Am J Hosp Pharm. 1994;51:3058–3060 |
| 2040 | Trissel <i>et al.</i> , Pharmaceutical properties of paclitaxel and their effects on preparation and administration. Pharmacotherapy. 1997; 17(5 Part 2):133S–139S |
| 2041 | Kattige, Long-term physical and chemical stability of a generic paclitaxel infusion under simulated storage and clinical-use conditions. Eur J Hosp Pharm-S P. 2006; 12(6):129–134 |
| 2042 | Lee <i>et al.</i> , Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharmacol Res. 2003; 20(7):1022–1030 |
| 2043 | Feng, <i>et al.</i> , Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biodegradable polymers. J Control Release. 2001; 71(1):53–69 |
| 2044 | Vilker <i>et al.</i> , The Osmotic Pressure of Concentrated Protein Solutions: Effect of Concentration and pH in Saline Solutions of Bovine Serum Albumin. J Colloid Interf Sci. 1981; 79(2):548–566 |
| 2045 | Fogh-Andersen <i>et al.</i> , Ionic Binding, Net Charge, and Donnan Effect of Human Serum Albumin as a Function of pH. Clin Chem. 1993; 39(1):48–52 |
| 2046 | Curnis <i>et al.</i> , Improving Chemotherapeutic Drug Penetration in Tumors by Vascular Targeting and Barrier Alteration. J Clin Invest. 2002; 110(4):475–482 |
| 2047 | Yuan, F., Transvascular Drug Delivery in Solid Tumors. Semin in Radiat Oncol. 1998; 8(3):164–175 |
| 2048 | <i>Intentionally Left Blank</i> |
| 2049 | <i>Intentionally Left Blank</i> |
| 2050 | Ziller <i>et al.</i> , Control of Crystal Growth in Drug Suspension: 1) Design of a Control Unit and Application to Acetaminophen Suspensions). Drug Dev Ind Pharm. 1988; 14(15–17):2341–2370 |
| 2051 | USP Monograph, Paclitaxel. 30(40):1279 http://www.pharmacopeia.cn/v29240/usp29nf24s0_m60190.html |
| 2052 | Garnett <i>et al.</i> , The effects of serum and human albumin on calcium hydroxyapatite crystal growth. Biochem J. 1990; 266:863–868 |

Filed on behalf of: Abraxis Bioscience, LLC

Filed: November 7, 2017

| | |
|-------------|--|
| 2053 | Kommanaboyina <i>et al.</i> , Trends in Stability Testing, with Emphasis on Stability During Distribution and Storage. Drug Dev Ind Pharm. 1999; 25(7):857–868 |
| 2054 | Surapaneni <i>et al.</i> , Designing Paclitaxel Drug Delivery Systems Aimed at Improved Patient Outcomes: Current Status and Challenges. ISRN Pharmacol. 2012; 1–15 |
| 2055 | Flynn, G.L., Solubility Concepts and Their Applications to the Formulation of Pharmaceutical Systems: Part I. Theoretical Foundations. PDA J Pharm Sci Tech. 1984; 38:202–209 |
| 2056 | Pyo <i>et al.</i> , Preparation and Dissolution Profiles of the Amorphous, Dihydrated Crystalline, and Anhydrous Crystalline Forms of Paclitaxel. Drying Technol. 2007; 25(10):1759–1767 |
| 2057 | Steinhardt <i>et al.</i> , Differences between Bovine and Human Serum Albumins: Binding Isotherms, Optical Rotatory Dispersion, Viscosity, Hydrogen Ion Titration, and Fluorescence Effects. Biochemistry-US. 1971; 10(22):4005–4015 |
| 2058 | U.S. Application No. 12/910,693, Notice of Allowance (mailed Dec. 27, 2011) |
| 2059 | Diaz <i>et al.</i> , Molecular Recognition of Taxol by Microtubules. J Biol Chem. 2002; 275(34):26265–26276 |
| 2060 | Chen <i>et al.</i> , Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemoth Pharm. 2015; 76:699–712 |
| 2061 | Evangelio <i>et al.</i> , Fluorescent Taxoids as Probes of the Microtubule Cytoskeleton. Cell Motil Cytoskel. 1998; 39:73–90 |
| 2062 | U.S. Application No. 12/758,413, Notice of Allowance (mailed Feb. 23, 2011) |
| 2063 | Declaration of Lisamarie LoGiudice |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.